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Abstract
Introduction: Ultrasonography (US) might have an added value to clinical examination in diagnosing early
rheumatoid arthritis (RA) and assessing remission of RA. We aimed to clarify the added value of US in RA in these
situations performing a systematic review.
Methods: A systematic literature search was performed for RA, US, diagnosis and remission. Methodological quality
was assessed; the wide variability in the design of studies prohibited pooling of results.
Results: Six papers on the added value of US diagnosing early RA were found, in which at least bilateral
metacarpophalangeal (MCP), wrists and metatarsophalangeal (MTP) joints were scanned. Compared to clinical
examination, US was superior with regard to detecting synovitis and predicting progression to persistent arthritis or
RA. Eleven papers on assessing remission were identified, in which at least the wrist and the MCP joints of the
dominant hand were scanned. Often US detected inflammation in patients clinically in remission, irrespective of
the remission criteria used. Power Doppler signs of synovitis predicted X-ray progression and future flare in patients
clinically in remission.
Conclusions: US appears to have added value to clinical examination for diagnosing of RA when scanning at least
MCP, wrist and MTP joints, and, when evaluating remission of RA, scanning at least wrist and MCP joints of the
dominant hand. For both purposes primarily power Doppler US might be used since its results are less equivocal
than those of greyscale US.
Introduction
The treatment of rheumatoid arthritis (RA) has improved
dramatically over past decades with the early and inten-
sive use of conventional disease modifying antirheumatic
drug (DMARD) strategies [1] and the introduction of
biological agents [2]. Treatment strategies with dose and
medication adjustments tailored to the individual patient
(tight control) to achieve a predefined level of low disease
activity, or preferentially, remission within a certain lim-
ited period of time (treat to target) [3] are nowadays used
for early RA [4]. It is widely accepted that early after the
onset of RA, there is a period of time (window of
opportunity) during which effective treatment can benefi-
cially alter the outcome of the disease in the long term
[5,6]. This requires prompt referral and recognition of
RA. Recently, new classification criteria [7] and new
remission criteria [8] have been published. In the new
classification criteria, it is suggested that imaging techni-
ques such as ultrasonography (US) may be used for addi-
tional information in joints clinically suspected of
arthritis [7]. Regarding remission criteria, a considerable
number of patients in clinical remission according to sev-
eral clinical criteria shows signs of inflammation on US
[9-11]. These findings imply that US may have added
value to clinical examination when diagnosing RA, or
evaluating remission in RA. For this purpose we would
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because assessment of all joints would be very time
consuming.
The aim of this systematic review is to clarify if US,
when used for diagnosing RA and for evaluating remis-
sion in RA, would give additional information to clinical
examination, to elucidate which minimal set of joints
should be assessed by US for these two purposes, and
by which modality, that is, power Doppler US (PDUS)
and/or greyscale US (GSUS).
Material and methods
A systematic literature search was performed in
PubMed, Embase and the Cochrane library for articles
published up to October 4, 2011. A list of relevant key-
words and synonyms for disease (RA, arthritis) and ima-
ging (ultrasonography) was compiled. Keywords,
including words of the title and abstract, and medical
subject headings (Mesh) were combined using Boolean
operators (AND, OR) (see Additional file 1). Included
studies were those on adult humans, published in the
English or Dutch language, either on diagnosing RA or
evaluating US signs of synovitis in RA patients who
were clinically in remission. We limited our study to the
signs of US inflammation and did not assess structural
joint damage. In the domain of diagnosis, assessing
structural change probably would not increase the addi-
tive value of US very much, given the already very sensi-
tive current 2010 American College of Rheumatology
(ACR) classification criteria. Second, there would have
been the problem of how to apply the US finding of
structural damage to the 2010 ACR classification cri-
teria. In the domain of remission, structural changes are
a sign of past inflammation only. Disagreements about
study inclusion were resolved by discussion; results are
based on full consensus. Excluded were reviews, editor-
ials, case reports and letters to the editor. One reviewer
(DTC) screened titles and abstracts. Relevant articles
were obtained and their reference lists were screened to
find additional studies. Data were extracted by one
reviewer (DTC) on year of publication, study population,
study design and duration, treatment, possible follow up,
number and type of joints under investigation, statistical
methods and US parameters.
We used an adaptation of the phases (levels) in diag-
nostic studies proposed by Sackett and Haynes to reflect
the clinical relevance of research data (Additional file 2,
box 1) [12]. All results were summarized descriptively.
Heterogeneity in study design and methods precluded
pooling the results. Methodological quality of studies on
diagnosing RA was assessed by the instrument Quality
Assessment of Diagnostic Accuracy Studies-2 (QUA-
DAS-2) [13], with an extra question on sample size. For
the studies evaluating remission a quality assessment tool
was not available; we created a quality items list
(Additional file 3). The quality assessments were per-
formed to check for possible flaws in study design and
analyses.
Results
Diagnosing RA
In our systematic search we found six papers on the
added value of US joint core sets in diagnosing RA
[14-19]. All studies can be considered phase three,
according to Sackett and Haynes. Arthritis was evalu-
ated using both GSUS and PDUS. For definitions of US
signs of inflammation see Table 1. In four of these stu-
dies wrists and metacarpophalangeal (MCP) joints were
assessed as the minimum [14-17]; study-one also evalu-
ated tendons [14], study-two also evaluated proximal
interphalangeal (PIP) joints [15], and the third study
extended the core set to metatarsophalangeal (MTP)
joints and larger joints, such as the shoulders, knees and
ankle [16]. The fourth study also included the distal
interphalangeal (DIP) and elbow joints [17]. In the fifth
study [18], painful joints and the adjacent joints of the
same joint region (if applicable) and their contralateral
joints were assessed, whereas the sixth study started
scanning painful joints only; during this study the proto-
col was changed to US of MCP joints, MTP joints and
knees bilaterally [19].
At the joint level, among anti-cyclic citrullinated pep-
tide (aCCP)-positive arthralgia patients (that is, those
having no clinically swollen joints) US predicted pro-
gression to clinically detectable joint inflammation of
the subset of joints showing a positive PDUS signal,
after a median follow up of 26 months, with an odds
ratio (OR) of 5.50 (95% CI 2.57, 11.9) [18]. Another
study showed that adding US parameters at baseline to
clinical parameters increased the pretest probability of
6% to 94% post test for the progression to inflammatory
arthritis at 12 month follow up at patient level. This was
evaluated among 30 rheumatoid factor (RF) and/or
aCCP-negative individuals with inflammatory hand
symptoms with or without clinical synovitis [14].
Among individuals with possible RA (n = 58), 10%
(three out of twenty-nine patients) were rightly classified
as RA patients by US at baseline, using the clinical diag-
nosis of RA at 1.5 years as the reference standard [16].
In 80 patients with early oligo-arthritis(< 12 months),
about 1/3 of patients could be reclassified as having > 5
inflamed joints when US was added to the clinical
examination, but 15 of all 185 joints (8%) with clinical
synovitis were normal on US examination [19]. This is
why the study extended its scan protocol halfway
through the study, from scanning only painful joints to
scanning MCP and MTP joints and knees bilaterally. In
one study in which the shoulders, elbows, wrists, MCP
joints, PIP joints, DIP joints, knees, ankles and MTP
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Table 1 Value of ultrasonography in diagnosing early (rheumatoid) arthritis
Author
(year)
[ref]
Phase*
Study population Number; type of joints or
tendons
US modality,
definition of
synovitis (A-F)
Outcome, Risk estimates (95% CI) Authors’ conclusions Limitations#
Filer
(2011) [16]
3
58 IA
22 RA
38; MCP, PIP, MTP, wrists,
elbows, shoulders, knees,
ankles
GSUS & PDUS
A
US reclassifies 3 of 29 IA patients to RA
(ACR 2010)
US of MCP, wrists and MTP improves optimally
clinical models to predict RA
Q4E
Freeston
(2010) [14]
3
30 patients with
inflammatory symptoms and
negative RF and aCCP tests
12; MCP, wrists and flexor
tendons of fingers
GSUS & PDUS
B
US increases pretest probability for
arthritis at one year from 6 to 94%
Inflammation at US predicts development of
arthritis in patients with inflammatory symptoms
and negative RF and aCCP tests
Q1D, Q2C
Ozgul
(2009) [17]
3
51 IA 50; shoulders, elbows wrists,
MCP, PIP, DIP, knees, ankles,
MTP
GSUS
C
Kappa = 0.61 for US diagnosis of RA
versus clinical diagnosis
Average agreement between US and clinical
examination when diagnosing RA
Q1A, Q1E,
Q4E
Salaffi
(2010) [15]
3
149 UA 18; wrists, MCP2-5, PIP2-5 GSUS & PDUS
D
Sensitivity 0.35 (0.24, 0.48) and
specificity 0.78 (0.67, 0.86) for US as
baseline test, predicting RA at 1 year
Presence of PDUS signs predicts progression
from UA to RA
Q1A, Q1C,
Q1E, Q3B,
Q4E
Stadt
(2010) [18]
3
192 RF and/or aCCP-positive
arthralgia patients, clinically
without arthritis
Painful joint + adjacent and
contralateral joints, mean 8
joints per patient
GSUS & PDUS
E
JE: OR = 3.07 (1.05, 8.9);
SH: OR = 5.5 (2.3, 12)
PD: OR = 5.5 (2.6, 12), all for future
arthritis
Inflammation at US predicts future arthritis in
aCCP-positive patients clinically without arthritis
Q4E
Wakefield
(2004) [19]
3
80,
Oligoarthritis
First 40 patients: only
symptomatic joints
Last 40 patients:
22; MTP, MCP, Knees
GSUS
F
1/3 of cases of oligoarthritis reclassified
to polyarticular (>= 6 joints) arthritis
GSUS detects inflammation in more joints than
clinical exam, but 8% of joints with clinical
synovitis are normal at US
Q2C
A, according to Szkudlarek 2003 [30], 2006 [31] and Wakefield 2005 [32]. B, semiquantitative definitions based on binary definitions by Brown 2006 [11], Wakefield 2004 [19], Karim 2004 [33] and Newman 1996 [34].
C, (a) joint capsule elevated beyond normal range, or (b) synovial hypertrophy or effusion around the joints, or (c) erosions of the joint margins, or (d) change in the diameter of the tendon with or without
peritendinous hypo-echogeneity supporting effusion. D, according to Wakefield 2005 [32] and Szkudlarek 2003 [30]. E, according to Szkudlarek 2003 [30]. F, abnormally hypo-echoic joint space, distinct from the
intra-articular fat pad and non-compressible with the transducer. Ref, reference; US, ultrasonography; GSUS, greyscale ultrasonography; PDUS, power Doppler ultrasonography; aCCP, anti-cyclic citrullinated peptide;
JE, joint effusion; IA, inflammatory arthritis; RA, rheumatoid arthritis; UA, undifferentiated arthritis; RF, rheumatoid factor; SH, synovial hypertrophy; OR, odds ratio. *Adaptation of phases according to Sackett and
Haynes (Additional file 2, box 1): Phase 1. Do US results in patients with the condition differ from those without the condition? Phase 2. Are patients with certain US results more likely to have the condition? Phase
3. Do US results distinguish patients with and without the condition among those in whom it is clinically sensible to suspect the condition? Phase 4. Do patients undergoing US fare better in their ultimate health
outcome than similar untested patients?. #See Additional file 3.
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joints were scanned, among 51 inflammatory arthritis
patients, the subgroup with US symmetric polyarthritis
was compared with the subgroup, who two years there-
after, met the ACR 1987 criteria for RA, yielding a
kappa statistic of 0.61, which denotes a reasonable level
of agreement [17].
In another study US at baseline reclassified 15% (n =
22) of the patients with undifferentiated arthritis (n =
149) to having RA, using the clinical diagnosis of RA
(n = 62) with a follow up of 12 months as reference,
while US in 11% (n = 17) was false positive at baseline.
For this study, as the cut-off for US inflammation, a
PDUS signal in more than three joints was used [15].
This suggest a US sensitivity of 0.35 (95% CI 0.24, 0.48)
and a specificity of 0.78 (95% CI 0.67, 0.86) for diagnos-
ing RA at baseline.
Quality assessment of studies reviewed for diagnosing RA
Details of quality assessment of studies are shown in
Table 1 and Additional file 3. Assessment of the metho-
dological quality using the QUADAS-2 [13], extended
with a question on sample size, showed relevant patients
in all six studies, who were followed over time in five
studies [15,16,18]. Both the index test (US) and refer-
ence (diagnosis of RA) were clearly described and
applied to all included patients, although semiquantita-
tive definitions of US inflammation used in one paper
eventually seem to be based on a paper using a binary
score and a paper describing synovitis of the knee [14].
Drop out of patients was mentioned in one of five longi-
tudinal studies [14].
Furthermore, in our interpretation small sample sizes
and heterogeneity of studies diminished the strength of
evidence of the value of US to improve early diagnosis
of RA [14-17].
Evaluation of remission of RA
Our systematic search yielded 11 papers on the added
value of US in the evaluation of remission in RA
[9-11,20-27], using sets of joints ranging from six [10]
to forty-four joints [26]. One study scanned forty-four
joints [26], two studies scanned forty-two [20,27], and
the other studies assessed between six and sixteen joints
[9-11,21-25]. Within the 11 studies, the wrist and MCP
joints of the dominant hand were always scanned.
Arthritis was evaluated by GSUS and PDUS. The defini-
tion of remission varied and included physician-deter-
mined remission [11,20,21], a disease activity score
(DAS) <1.6 [23,26], and complete absence of clinical
and laboratory symptoms [9], while the time since
remission varied from 2 months [9,20,22] to 3 months
[26], or to more than 6 months [10,11,21,23-25]. One
study evaluated the time to remission in a treatment set-
ting [27]. Study characteristics, definitions of US signs of
inflammation and outcomes are presented in Table 2.
In all 11 papers, there was a discrepancy between the
number of clinically swollen joints and the higher number
of joints with US signs of arthritis, indicating that joints
that were not clinically inflamed showed US signs of
arthritis. In five of these eleven papers it was explicitly
mentioned that US evidence of synovitis was also found in
joints that were not clinically inflamed [10,11,23,24,26].
There seemed to be no clear association between the
number of joints scanned per patient and the number of
patients with at least one joint with US signs of synovitis.
When looking at GSUS signs of synovitis, all 11 studies
identified synovitis in 73 to 95% of patients in clinical
remission; for PDUS signs of synovitis, the range was 8.7
to 62% [9-11,20-27].The predictive ability of US for clinical
flares was evaluated in four studies [22,23,25,26]. Three of
these identified predictive value, where one did not [25].
One study reported an OR of 3.6 (95% CI 1.4, 9.0) for the
occurrence of flare in PDUS-positive patients when scan-
ning the wrists, and the second and third MCP and PIP
joints, all bilaterally [23]. In another study, PDUS signs of
synovitis were associated with an OR of 6.3 (95%CI 2.0,
20) [22] for the occurrence of flare within one year among
patients in clinical remission (DAS44 < 2.4) when scan-
ning the wrists, and the second, third and fifth MCP and
MTP joints, all bilaterally. In a study assessing 44 joints
among patients in remission, PDUS signs of synovitis pre-
dicted flare with an OR of 13 (95%CI 1.6,104) [26]. The
predictive value of GSUS was either not significant
[22,25,26] or not presented [23].
Two of the eleven papers evaluated progression of radi-
ological joint damage in patients in clinical remission.
The presence of PDUS signs of inflammation increased
the risk of joint damage with an OR of 1.4 (95%CI 1.1,
1.9) at the patient level in a study of nine patients with
radiographic signs of progression [22]. At the joint level,
presence of PDUS signs of inflammation predicted pro-
gression with an OR of 12 (95%CI 3.3, 44) in a study of
10 patients [21]. GSUS scores were significantly higher in
the group that progressed vs. the group that did not pro-
gress (mean 4.8 ± SD 2.3 vs. 3.2 ± 2.6) [22], or they pre-
dicted radiographic progression with an OR of 1.92 (95%
CI 0.49, 7.24) [21].
The impact of using different remission criteria was
reported in five studies. Two of these studies presented
discrepancies between the prevalence of inflammation
detected by US if applying different remission criteria. The
first of these two studies showed that among patients in
remission according to the simplified disease activity index
when using a cutoff point of less than 3.3 (SDAI score <
3.3), the number of joints with PDUS signs of synovitis
was smaller, and the PDUS grade of synovitis was lower
when compared to those of patients in remission when
using a cutoff point of less than 5.5 on the SDAI (SDAI
score < 5.5), the DAS28 (cutoff score < 2.4 or < 2.6) or
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Table 2 Value of ultrasonography in remission of rheumatoid arthritis
Author (year)
[ref] Phase*
Study population,
duration of remission
or LDA (definition)
Number;
type of joints
US
modality,
definition
of
synovitis
(A-F)
Outcome¶ Risk estimates (95%
CI)
Authors’ conclusions Limitations#
Balsa (2010) [20]
2
97 RA in remission >2
months (physician’s
judgment); 88 controls
42; PIP, MCP,
wrists, elbows,
shoulders,
knees, ankles,
MT, MTP
GSUS &
PDUS
A
Of RA in remission, 92% GSUS-
positive and 42% PDUS-positive;
88% of non-arthritic controls
GSUS-positive
Of sets ARA 1981,
DAS28 and SDAI, the
SDAI is closest to the
absence of
inflammation on US
j,o
Brown (2006) [11]
2
107 RA in remission > 6
months (physician’s
judgment)
8; MCP2-5,
wrist (RC, IC,
DRU, UC) of
dominant
hand
GSUS &
PDUS
B
73% GSUS-positive
43% PDUS-positive
In many patients in
remission, inflammation
is found on US
o,x
Brown (2008) [21]
2
102 RA in remission > 6
months (physician’s
judgment)
8; MCP2-5,
wrist (RC, IC,
DRU, UC) of
dominant
hand
GSUS &
PDUS
B
PDUS predicts radiographic
progression at one year: OR = 12
(3.3, 44)
Presence of PDUS
predicts radiographic
progression in joints of
patients in remission
o,v,x
Foltz (2011) [22]
2
85 RA in remission or
with LDA > 2 months
(DAS < 2.4)
14; wrists,
MCP2,3,5,
MTP2,3,5
GSUS &
PDUS
A
PDUS predicts flare: OR = 6.3
(2.0, 20); PDUS predicts
radiographic progression: OR =
1.4 (1.1, 1.9)
Inflammation on PDUS
predicts radiographic
progression and flare
of patients in remission
or with LDA
o,q,v
Ozgocmen (2008)
[9]
1
52 RA of whom a
subgroup in remission
> 2 months (Preliminary
ARA 1981 + DAS < 3.2)
14; MCP1-5,
wrists (USTL,
RSTL)
GSUS &
PDUS
C
62% of 32 patients (in ARA 1981
remission) PDUS-positive
58% of 31 patients (in DAS28
remission) PDUS-positive
PDUS inflammation is
found for 2 different
remission criteria sets,
in a similar number of
patients
i,j,k,l,o,r,t,
Peluso (2011) [23]
2
48 early (7 months) RA
in remission > 6
months (DAS < 1.6)
46 LSRA (118 mo.) in
remission > 6 months
(DAS < 1.6)
12; MCP2-3,
PIP2-3, wrists
(RC, UC)
GSUS &
PDUS
Not given
56% early RA
GSUS-positive;
83% LSRA GSUS-positive;
PDUS predicts flare:
OR = 3.6 (1.4, 9.0)
PDUS shows predictive
value for flare
In many patients in
remission, inflammation
is found on US
g,i,l,n,o,p,r,t,u,
v
Saleem (2009) [24]
2
100 RA in remission > 6
months (DAS < 2.6)
16; wrists (RC,
UC,IC), MCP1-
5
GSUS &
PDUS
D
88% GSUS-positive
PDUS-positive 58%
In > 55% of patients in
remission inflammation
is found on PDUS
i,o,r,x
Saleem (2010) [25]
2
47 RA in remission > 6
months (DAS28 < 2.6)
of whom a subgroup of
20 patients is assessed
also by US
18; wrists, PIP,
MCP
GSUS &
PDUS
F
In group that flared after 2 years,
at baseline 88% GSUS-positive
and 44% PDUS-positive. In group
that did not flare after 2 years, at
baseline 82% GSUS-positive and
45% PDUS- positive
In many patients in
remission inflammation
is found on PDUS, but
does not predict flare
o,r,u,v,w,x
Saleem (2011) [10]
2
128 RA in remission > 6
months (ACR 2011)
6; wrist,
MCP2-5 of the
dominant
hand
GSUS &
PDUS
D
Around 50% PDUS-positive when
using ACR2011, DAS28, SDAI
remission sets
For 3 different
remission criteria sets a
similar number of
patients is PDUS-
positive
c,h,i,j,k,l,o,p,r,
t,u,v,x
Scire (2009) [26]
2
106 early RA (<12
months), of whom
43 in remission > 3
months (DAS < 1.6)
44; shoulders,
elbows, wrists,
MCP, PIP,
knees, ankles,
MTP
GSUS &
PDUS
E
95% GSUS-positive, 41% PDUS-
positive
PDUS positivity predicts flare: OR
= 13 (1.6, 104)
In many patients in
remission, inflammation
found on PDUS,
predictive of flare
g,i,j,k,l,m,p,r,t,
u,v
Wakefield (2007)
[27]
3
10 early (<12 months)
RA in remission (DAS28
< 2.6)
42; shoulders,
elbows, wrists,
MCP, PIP,
knees,
tibiotalar, MT,
MTP
GSUS &
PDUS
Not given
50% GSUS-positive and 15%
PDUS-positive in clinically normal
joints
In many RA-patients in
remission, PDUS
inflammation is found
i,n,t,x
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slightly modified ACR 1981 remission criteria (that is,
excluding the fatigue criterion). In this study 42 joints
were scanned [20]. The second of these two studies
showed that using the ACR 1981 remission criteria, the
number of patients with US inflammation was smaller
compared to applying the criterion of a DAS < 1.6 [23]. In
this study 12 joints in the hands and wrists were scanned.
The three other studies reporting on the impact of using
different remission criteria showed that 60 to 80% of their
patients had GSUS signs of inflammation independently of
the specific criteria used [9-11]. Regarding PDUS signs of
inflammation, two of these three studies showed that
these signs were present in about 50% of the patients in
clinical remission when scanning the MCP joints and the
wrist of the dominant hand [10,11]. The third study, in
which a greater number of joints was scanned, showed
similar results: about 60% of the patients in clinical remis-
sion showed, irrespective of the clinical remission criteria
used, PDUS signs of inflammation when scanning the
wrists (ulnar and radial styloid regions) and the first to
fifth MCP joints, all bilaterally [9].
The influence of disease duration was studied in one
paper, assessing 12 joints in the hands and wrists. Among
patients who were in clinical remission, 44% of those
with early RA had no US signs of synovitis (defined as
absence of GSUS and PDUS signs of inflammation) vs.
17% of those with longstanding RA. When defining syno-
vitis as presence of GSUS synovitis and absence of PDUS
synovitis, 15% of those with early RA had US signs of
synovitis, as opposed to 52% of the patients with long-
standing RA. When defining synovitis as presence of
both GSUS and PDUS signs of inflammation, 42% of the
patients with early RA showed signs of US inflammation,
as opposed to 30% of those with longstanding RA [23].
Quality assessment of studies reviewed for evaluation of
remission of RA
Details of quality assessment are shown in Table 2 and
Additional file 3. Quality assessment was performed for
all studies but longitudinal studies are the most relevant
to evaluate the remission of RA. Two of these studies
evaluated the added value of US for prediction of radio-
graphic progression among patients in remission, and
four studies evaluated the value for prediction of flare.
We found wide CIs and point estimates differing from
study to study, probably due to small sample sizes,
slightly different definitions for remission and flare and
analyses performed at joint level and at patient level.
Definitions of US inflammation are not clearly described
in three of the eleven papers [23,25,27]. In four other
longitudinal studies the semiquantitative definitions of
US inflammation used for inflammation in MCP joints
and wrists seem to be based on a paper using a binary
score and a paper describing synovitis of the knee
[10,11,21,24].
Discussion
The results of our systematic search indicate that when
diagnosing RA a greater number of inflamed joints per
patient was detected by US compared to clinical exami-
nation in populations ranging from aCCP/RF-positive
patients with arthralgia, to patients with clinically
observed arthritis. The presence of US signs of inflam-
mation seems to increase the risk of progression to per-
sistent arthritis or RA, implying clinical relevance.
Regarding assessment of remission, our review shows
that in many patients with low disease activity or in
clinical remission, US signs of inflammation were
detected, even in those who met stringent clinical remis-
sion criteria. These findings are relevant, because the
results of these studies suggest that PDUS signs of syno-
vitis predict progression of radiographic joint damage
and flare. We limited our study to signs of US inflam-
mation and did not assess structural joint damage. The
reason for this is that in the publication of the new clas-
sification criteria, in which erosions are not included, it
was suggested that US may be used to confirm clinical
findings, i.e. swelling of the joint. Erosions typical of RA
would imply the classification of RA in patients who
met the new classification criteria in the past. However,
the new classification criteria are very sensitive: the
diagnosis of RA can be made on the basis of one swol-
len joint, so one could argue that for these new criteria,
the finding of erosions would not add much to the sen-
sitivity in early RA, in contrast to the situation with the
A, according to Wakefield 2005 [32]. B, semi quantitative definitions based on binary definitions by Brown 2006 [11], Wakefield 2004 [19], Karim 2004 [33] and
Newman1996 [34]. C, GSUS: Hypoechogeneity; PDUS: grade 0, no flow signal in the synovium; grade 1, separate dot signals or short linear signals; grade 2,
clearly discernible vascularity with either many small vessels or several long vessels with or without visible branching, though involving less than half the area of
the synovium; grade 3, vessels involving more than half the area of the synovium. D, semiquantitative definitions based on binary definitions by Brown 2006
[11], Wakefield 2004 [19], Karim 2004 [33]. No PDUS definitions. E, Wakefield 2005 [32] and Newman 1996 [34]. F, according to Outcome Measures in
Rheumatology (OMERACT) definitions, but not clear from footnotes which definitions have been used. US, ultrasonography, GSUS, greyscale ultrasonography;
PDUS, power Doppler ultrasonography; aCCP, anti-cyclic citrullinated peptide; JE, joint effusion; SH, synovial hypertrophy; IA, inflammatory arthritis; LDA, Low
disease activity; LSRA, long standing RA; RA, rheumatoid arthritis; UA, undifferentiated arthritis; RF, rheumatoid factor; OR, odds ratio; DRU, distal radio-ulnar; IC,
intercarpal; MT, midtarsal; RC, radiocarpal; RSTL, radial styloid; USTL, ulnar styloid; UC, ulnocarpal; SDAI, simplified disease activity index. *Adaptation of phases
according to Sackett & Haynes (Additional file 2, box 1): Phase 1. Do US results in patients with the condition differ from those without the condition? Phase 2.
Are patients with certain US results more likely to have the condition? Phase 3. Do US results distinguish patients with and without the condition among those
in whom it is clinically sensible to suspect the condition? Phase 4. Do patients undergoing the US fare better in their ultimate health outcome than similar
untested patients? # See Additional file 3. ¶GSUS pos. (%) and PDUS pos. (%) signify the percentages of individuals with at least one inflamed joint applying the
respective US modality.
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1987 criteria. Second, there would have been the pro-
blem of how to apply the finding of structural damage,
assessed by US, to the 2010 ACR classification criteria,
that is, what would be the contribution of structural
damage assessed by US to the diagnosis, applying the
2010 criteria? In the domain of remission, structural
damage reflects inflammation in the past, not the cur-
rent inflammatory state.
An important question is, which joints should be
scanned? Scanning only the joints that are painful or
clinically show arthritis does not seem to be a valid
strategy, and scanning all joints is not feasible in daily
practice. Based on the spectrum of joints most fre-
quently involved in early RA and the results of this
review, a recommendation when scanning for diagnosis
of early RA could be to scan at the minimum the wrists,
MCP and MTP bilaterally using PDUS; PIP joints could
be included based on the results of one study. Also in
the domain of remission of RA it is important to iden-
tify which joints to scan. Although more signs of arthri-
tis are found when scanning a larger number of joints, a
clear relation between the number of joints scanned and
the number of patients clinically in remission with US
signs of synovitis seems lacking. Therefore, it might be
sufficient to scan a limited set of joints for this purpose.
In eleven studies the wrist and MCP joints of the domi-
nant hand had been scanned as the minimum.
Based on the results of this review it seems that it is
not necessary to scan large joints when diagnosing RA
or evaluating the remission of RA. In general, the more
joints that are scanned, the higher the chance of finding
US signs of arthritis in a patient. An earlier diagnosis
leads to earlier initiation of adequate therapy, more
often within the window of opportunity. This not only
improves the prognosis in the short term, for example,
by inducing remission at an earlier stage and more fre-
quently, but possibly it also favorably alters the long-
term course of the disease.
Another important question is which modality to use,
PDUS or GSUS? Our systematic search indicates that
PDUS in particular may have an added value in the
diagnosis of early RA and evaluation of the remission of
RA: the predictive value of PDUS was higher than that
of GSUS. This is in line with the findings that GSUS
signs of inflammation also occur in non-arthritic indivi-
duals [20]. In a study in an osteoporosis outpatient
clinic, GSUS signs of synovitis were detected in up to
88% of 16 individuals who were without clinical symp-
toms or signs of joint disease (controls), based on scan-
ning 42 joints with a cutoff of at least one joint with a
score of 1 according to the OMERACT criteria for syno-
vial hypertrophy [20]. Of all 672 joints scanned, 76
joints showed GSUS signs of synovitis, 64 of them with
grade 1, 12 with grade 2, and none with grade 3 signs.
In another study, in which a total of 84 joints was
scanned among nine healthy individuals, 23 joints
showed GSUS grade 1 signs of inflammation and only
one joint was scored grade 2; no joints had a grade 3
score [18]. It seems that for the purpose of discriminat-
ing arthritis patients from non-arthritic patients, the use
of the GSUS grade 1 score is debatable. Also in RA
patients it is not clear what the significance of GSUS
grade 1 is. One study states that in longstanding RA,
GSUS might depict chronically thickened tissue without
inflammation [23]. At the patient level, a cumulative
GSUS score for discriminating arthritis patients from
non-arthritic patients has yet to be determined. A cutoff
of 8 when scanning 22 joints has been proposed [28].
Although the predictive value of PDUS is higher than
that of GSUS to predict early RA, flare of RA and radio-
graphic progression, PDUS has limitations as well. It is a
technique that is particularly operator-, machine- and
setting-dependent [29]. It is important to avoid pressure
on the transducer, and motion artifacts, and to use the
correct US settings, for example, wall filter and pulse
repetition frequency should be low when assessing
joints.
Although the study results in our systematic review
generally were not conflicting for either diagnosis or
remission, some considerations need to be made. For
instance, the number of diagnostic studies is currently
limited, and only one study has focused on the ACR/Eur-
opean League Against Rheumatism (EULAR) 2010 cri-
teria. Furthermore, regarding the quality of studies, the
longitudinal studies looking at events (flares or radio-
graphic progression) are small, causing a wide variation
in the US risk estimates. Also, the variables that have
been shown to be predictors of the diagnosis of RA or of
remission, such as radiographic joint data and aCCP test
results, have not all been taken into account. This might
have inflated the added value of US. In addition, clear
definitions for US signs of inflammation were not always
given.
Something else to consider is that some of the papers
reviewed are from the same group [10,11,19,21,24,25,27].
Data presented in these papers might not be independent
of each other, with correlated results being biased in one
or the other direction. However, the results from the stu-
dies in our review are based on different patient popula-
tions. Also, we did not find signs that this group may be
evidently pro or contra US, such that it would affect their
scientific integrity, especially since one of the papers
from this group shows a lower predictive value of US
compared to those in other reviewed papers. Large pro-
spective longitudinal studies are necessary to evaluate the
additional value of US in diagnosing RA, scanning joints
and evaluating the predictive validity of other signs such
as US-detected tenosynovitis.
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Conclusions
In conclusion, although further research is needed,
PDUS has additional value to clinical examination both
in improving early diagnosis of RA and establishing true
RA remission. GSUS seems less specific. In the diagnos-
tic process, studies suggest that as a minimum the wrist,
MCP and MTP joints should be scanned bilaterally,
while for remission, studies suggest that as a minimum
the wrist and MCP joints of the dominant hand should
be scanned.
Additional material
Additional file 1: Search strategies. Both for the domain of early
rheumatoid arthritis (RA) and remission a separate search strategy for
PubMed and Embase is presented, as well as a flow chart.
Additional file 2: Adaptation of the diagnostic phases (levels) of
Sackett and Haynes. Adaptation of Sackett and Haynes phases (levels)
of diagnostic questions in diagnostic studies to reflect the clinical
relevance of the reviewed studies.
Additional file 3: Quality assessment lists. For the domain of early
rheumatoid arthritis (RA) we used the Quadas-2, with an extra question
on sample size. For the studies evaluating remission, no quality
assessment tool was available, therefore we created a quality items list to
evaluate these studies.
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